Skip to content

Ketamine: all studies

Page 51 of 448: studies 501 to 510 of 4,475, newest first. Back to the ketamine overview

Research

Translational Regulation in Excitatory Neurons Controls Stress Reactivity and the Antidepressant Response to Ketamine

2026 Sebastian Baranyi Nicholls

Major depressive disorder (MDD) is a leading cause of disability worldwide, with nearly one-third remaining treatment-resistant. Chronic stress is a major risk factor for MDD, whereas acute stress is adaptive and mediated by hypothalamic-pituitary-adrenal axis activation. Ketamine produces rapid antidepressant effects, partly through mammalian target of rapamycin complex 1 (mTORC1) signalling,...

DOI: 10.22215/etd/2026-17222 (opens in new tab) Ketamine Excitatory postsynaptic potential Antidepressant Fight-or-flight response +7

Challenges of enrolling participants with alcohol and opioid use disorders in the emergency department for clinical trials of ketamine: The experience from two randomized controlled trials.

General Hospital Psychiatry 2026 Peter R. Chai, E Lee, M A Hasdianda et al.

Application of psychedelics including ketamine may be important adjuncts in the treatment of alcohol and opioid use disorders. Most patients with alcohol or opioid use disorder (AUD/OUD) may present to the emergency department (ED) seeking care both for substance use and associated complaints. Understanding safety and preliminary efficacy of ketamine and other psychedelics to improve the care...

L-tetrahydropalmatine attenuates ketamine reward effect via modulating the miR-27a-3p/MAP2K4 axis.

Frontiers in Genetics 2026 Yan Du, Xing-Cui Gao, Qing Ma et al.

Ketamine (KET) addiction has already been a serious problem all over the world, which could induce neurological and psychological harm. Levo-tetrahydropalmatine (l-THP), a major alkaloid extracted from the Chinese medicinal plants Corydalis and Stephania, has been shown to attenuate ketamine (KET) induced conditioned place preference (CPP) in rats. Nevertheless, the precise mechanism remains...

DOI: 10.3389/fgene.2026.1701742 (opens in new tab) Full text (opens in new tab) Bdnf-trkb L-tetrahydropalmatine Map2k4 Mir-27a-3p +1

Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2026 Yanhong Li, Kuangyu Zhao, Peipei Cao et al.

Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...

Sex, drugs, and arousal-two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity.

Therapeutic Advances in Psychopharmacology 2026 Manfred Klöbl, Thomas Liebe, Gregor Dörl et al.

Ketamine, a well-established antidepressant and dissociative anesthetic, is also used recreationally in the club and chemsex scene. Survey and qualitative data suggest that while ketamine facilitates chemsex encounters, it diminishes the intensity of the sexual experience. To investigate this phenomenon from a neuroscientific perspective while considering ketamine's sex-specific effects. Two...

Sympathetic activation but not dissociation linked to ketamine's sustained antidepressant effect.

Therapeutic Advances in Psychopharmacology 2026 Veronika Andrashko, Tomáš Novák, Miloslav Kopecek et al.

Ketamine is a rapid-acting antidepressant with robust evidence, but unclear predictors of therapeutic response. Based on previous knowledge, hemodynamic parameters and acute altered state of consciousness have been hypothesized as potential correlates of subsequent antidepressant outcome. A post hoc analysis was performed using the data from an open-label study, in which 39 patients with...

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs.

Frontiers in Psychiatry 2026 Ngo Cheung 6 citations

Rapid-acting antidepressants show that mood can lift within hours when glutamatergic circuits shift from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity®) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a...

Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment-Resistant Depression.

Journal of Neuroscience Research 2026 Stephanie N Njau, Artemis Zavaliangos-Petropulu, Shantanu Joshi et al.

Ketamine has emerged as a highly effective intervention for treatment-resistant depression (TRD). Though it acts as a non-competitive antagonist of excitatory N-methyl-D-aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ-aminobutyric acid (GABA)-ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate...

Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience.

General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation

Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.

Frontiers in Psychiatry 2026 C M Diendorfer, C Bum, Ana Weidenauer et al.

Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...

DOI: 10.3389/fpsyt.2026.1766485 (opens in new tab) Full text (opens in new tab) Ketamine Depressive symptoms Glutamate Negative symptoms schizophrenia